Trial
NCT03236311
A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Microvascular Coronary Artery Disease
Intervention
SAR407899
Why stopped
(Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-24